Ken Griffin Xortx Therapeutics Inc. Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$0.45 - $0.81 $12,649 - $22,768
28,109 New
28,109 $18,000
Q4 2022

Feb 14, 2023
BUY
$0.73 - $10.71 $12,878 - $188,945
17,642 New
17,642 $14,000

About XORTX Therapeutics Inc.

XRTX Quotes by TradingView
  • Ticker XRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,389,700
  • Market Cap $15.8M
  • Description
  • XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic ki...
More about XRTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email